menu
    • menu

    Company profile for NeuroSense Therapeutics

    NEW Drugs in Dev: 4
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NeuroSense Therapeutics is a drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. The rationale behind the novel pathological targets of our drug, PrimeC, is supported by highly respected ALS experts and global Key Opinion Leaders, such as Professor Jeremy Shefner and Professor Vivian Drory. In pre-clinical studies, PrimeC showed outstanding results, w...
    NeuroSense Therapeutics is a drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. The rationale behind the novel pathological targets of our drug, PrimeC, is supported by highly respected ALS experts and global Key Opinion Leaders, such as Professor Jeremy Shefner and Professor Vivian Drory. In pre-clinical studies, PrimeC showed outstanding results, which were significantly better than any other outcome seen in this model before. NeuroSense Therapeutics is currently running two clinical trials in ALS patient.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NeuroSense TherapeuticsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    85 Medinat Hayehudim, Herzeliya
    Telephone
    Telephone
    +972-9-9531142
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurosense-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/neurosense-therapeutics?trk=company_logo
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/NeurosenseT

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurosense Receives U.S. Patent For Alzheimer's Disease Treatment
    Neurosense Receives U.S. Patent For Alzheimer's Disease Treatment

    21 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurosense-granted-us-patent-for-treatment-of-alzheimers-disease-302666624.html

    PR NEWSWIRE
    21 Jan 2026
    Share Share
    Neurosense Reports Primec's Safe Use In Alzheimer's Ph2 Study
    Neurosense Reports Primec's Safe Use In Alzheimer's Ph2 Study

    22 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/neurosense-confirms-favorable-safety-and-tolerability-of-primec-in-an-alzheimers-phase-2-study-302648031.html

    PR NEWSWIRE BIO
    22 Dec 2025
    Share Share
    Neurosense Plans Pre-NDS Meeting With Health Canada In April 2026
    Neurosense Plans Pre-NDS Meeting With Health Canada In April 2026

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurosense-to-hold-pre-nds-meeting-with-health-canada-in-april-2026-302632989.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    Neurosense Cleared For Primec Phase 3 Trial In ALS
    Neurosense Cleared For Primec Phase 3 Trial In ALS

    24 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurosense-receives-fda-clearance-to-initiate-pivotal-phase-3-trial-for-primec-in-als-302624616.html

    PR NEWSWIRE
    24 Nov 2025
    Share Share
    Neurosense To Host Investor Webinar On December 8, 2025
    Neurosense To Host Investor Webinar On December 8, 2025

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurosense-to-host-investor-webinar-on-december-8-2025-302602495.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Neurosense's Primec Shows Significant Alzheimer's Biomarker
    Neurosense's Primec Shows Significant Alzheimer's Biomarker

    06 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurosense-primec-produces-statistically-significant-reductions-in-alzheimers-disease-biomarkers-302575654.html

    PR NEWSWIRE
    06 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search